GLPG1837 has advanced into a phase 2 clinical trial for Cystic Fibrosis people with the G551D, or S1251N class III mutation. This will be the first of two, phase 2 clinical trials testing the drug in CF. The Galapagos press release is here Galagapos starts SAPHIRA Phase 2 study. In a previous post we compared the phase 1 clinical trial results of GLPG1837 and Concert's CTP-656 side by side, CTP-656 & GLPG1837 Drug Comparison. The drug will be dosed twice daily, and the trial should be complete by the end of 2016. Thank you for reading.
No comments:
Post a Comment